Joe Turner, former Chief Financial Officer at Myogen (now Gilead (NASDAQ: GILD)), has joined the privately held Los Angeles-based Kythera Biopharmaceuticals Board of Directors. Not only is Joe an incredibly talented executive and individual but most selfishly he too has had a profound impact upon my personal life and professional development, and for that I will always be grateful as well as look forward to some day being positioned to pass along a fraction of the insight and wisdom that was bestowed onto me.
To attempt to summarize the value Kythera is receiving in only a sentence or two seems unfitting nevertheless…a few highlights of Joe’s track record include: responsibility for eight equity offerings which include three public offerings (IPO’s) raising in aggregate approaching approximately half-a-billion dollars, truly amazing! Most recently Joe helped to orchestrate San Diego-based NovaCardia’s $350M exit to Merck (NYSE: MRK) and he continues to sit on additional Boards including privately held Sequel Pharmaceuticals, a NovaCardia spin-out and SGX Pharmaceuticals (NASDAQ: SGXP).
Kythera with two Phase II compounds and a third preparing for PII along with financial backers Arch Venture Partners, Prospect Venture Partners, Versant Ventures and Altitude Life Science Ventures and now Joe Turner on the Board one might venture to guess that perhaps an IPO may be in their not too distant future?
***NOTE*** Take a look at the new Boulder Biotech Company Tree (HERE)!
***NOTE*** Read the new eBook CLSDF 2007 - What's In A Year? (HERE)!
If you enjoyed this post get free email or RSS updates (here).